Since adenoviral E1A and E1B share functional similarities with HPV E7 and E6, respectively, in their ability to inactivate the tumor suppressors pRB and p53, it is feasible to design adenoviral vectors with enhanced replication specificity in HPV-positive cancer cells. Here, TP53 is linked to neoplasm.